Brigatinib is a small-molecule targeted anti-cancer therapy marketed as Alunbrig for ALK-positive non-small cell lung cancer. It inhibits ALK and additional kinase pathways and has activity in resistant disease contexts. It is a prescription oral medicine with FDA approvals in both second-line and first-line metastatic NSCLC settings.
Mayo Clinic researchers found that Brigatinib, an FDA-approved lung cancer drug, can block survival pathways in ovarian cancer cells when combined with PARP inhibitors, potentially overcoming treatment resistance.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06813079 |
Using Tumor Models to Determine Treatments |
NOT_YET_RECRUITING | PHASE2 |
| NCT06532149 |
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
RECRUITING | |
| NCT06522360 |
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) |
WITHDRAWN | PHASE2 |
| NCT06132867 |
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults |
COMPLETED | PHASE1 |
| NCT05834348 |
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. |
COMPLETED | |
| NCT05721950 |
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) |
ACTIVE_NOT_RECRUITING | |
| NCT05718297 |
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer |
WITHDRAWN | PHASE2 |
| NCT05361564 |
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. |
UNKNOWN | PHASE2 |
| NCT05100069 |
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer |
RECRUITING | |
| NCT04925609 |
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
